Cronos Group (CRON) Stock Price, News & Analysis

Company Overview

Cronos Group Inc. is a Toronto-based cannabinoid company that develops, produces, and commercializes cannabis and cannabis-derived products. The company serves both the adult-use and medical cannabis markets, with activities spanning cultivation, product development, manufacturing, and brand marketing.

Cronos offers cannabis flower, pre-rolls, vaporizers, edibles, extracts, and other cannabis formats through brands including Spinach, PEACE NATURALS, and Lord Jones. Its products are distributed primarily through regulated cannabis channels, including provincial retail systems and medical or international markets where permitted by local laws.

Founded in 2013, Cronos has expanded through brand development, product innovation, and strategic partnerships. The company is led by Executive Chairman and Chief Executive Officer Mike Gorenstein and is headquartered in Toronto, Ontario. Its operations and commercial activities are focused on Canada, with additional international opportunities pursued in jurisdictions that permit cannabis-related products.

Key Stats

• Today's Range: $3.31 to $3.41
• 50-Day Range: $2.72 to $3.55
• 52-Week Range: $2.28 to $3.61
• Volume: 747,957 shs
• Average Volume: 1.10 million shs
• Market Capitalization: $1.24 billion
• P/E Ratio: 16.85
• Dividend Yield: N/A
• Price Target: $2.30
• Consensus Rating: Hold

Cronos Group Stock Analysis - MarketRank™

Cronos Group scored higher than 31% of companies evaluated by MarketBeat, and ranked 743rd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Cronos Group has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and no sell ratings.

Downside Risk

Cronos Group has a consensus price target of $2.30, representing about 31.8% downside from its current price of $3.37.

Amount of Analyst Coverage

Cronos Group has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Cronos Group is 16.85, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.68.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cronos Group is 16.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.27.

Price to Book Value per Share Ratio

Cronos Group has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.95% of the float of Cronos Group has been sold short.

Short Interest Ratio / Days to Cover

Cronos Group has a short interest ratio ("days to cover") of 2.14, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cronos Group has recently decreased by 4.00%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cronos Group does not currently pay a dividend.

Dividend Growth

Cronos Group does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.86

News Sentiment

Cronos Group has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Cronos Group this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for CRON on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

MarketBeat Follows

9 people have added Cronos Group to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cronos Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.80% of the stock of Cronos Group is held by insiders.

Percentage Held by Institutions

8.71% of the stock of Cronos Group is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/17/2026
• Investor update: 9/24/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:CRON
• CIK: 1656472
• Web: www.thecronosgroup.com
• Phone: (416) 504-0004
• Fax: N/A
• Employees: 610
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Cronos Group: $2.30
• High Price Target: $2.30
• Low Price Target: $2.30
• Potential Upside/Downside: -31.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.40
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.20
• Trailing P/E Ratio: 16.85
• Forward P/E Ratio: 30.64
• P/E Growth: N/A
• Net Income: -$9.45 million
• Net Margins: 39.08%
• Pretax Margin: 38.23%
• Return on Equity: 4.85%
• Return on Assets: 4.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.18
• Quick Ratio: 15.25

Sales & Book Value

• Annual Sales: $179.09 million
• Price / Sales: 6.94
• Cash Flow: $0.01 per share
• Price / Cash Flow: 262.42
• Book Value: $3.00 per share
• Price / Book: 1.12

Miscellaneous

• Outstanding Shares: 368,543,000
• Free Float: 339,797,000
• Market Cap: $1.24 billion
• Optionable: Optionable
• Beta: 0.94